Last reviewed · How we verify
DNA intercalators — Competitive Intelligence Brief
phase 2
DNA intercalator
DNA (double helix)
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
DNA intercalators (DNA intercalators) — UNICANCER. DNA intercalators insert themselves between DNA base pairs to disrupt DNA replication and transcription, leading to cancer cell death.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| DNA intercalators TARGET | DNA intercalators | UNICANCER | phase 2 | DNA intercalator | DNA (double helix) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (DNA intercalator class)
- UNICANCER · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- DNA intercalators CI watch — RSS
- DNA intercalators CI watch — Atom
- DNA intercalators CI watch — JSON
- DNA intercalators alone — RSS
- Whole DNA intercalator class — RSS
Cite this brief
Drug Landscape (2026). DNA intercalators — Competitive Intelligence Brief. https://druglandscape.com/ci/dna-intercalators. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab